Lab data

Peptide test results: how often research peptides fail lab tests

How often do research peptides pass an independent lab test? Recent results for 14 peptides from a public testing database, with what a fail means and where each one stands with FDA.

12 November 2026 5 min read By Peptide AI Editorial policy

Across 14 peptides with enough public test results to count, 1,397 of the last 2,415 samples with a result passed and 1,018 failed: 58 percent of peptide test results were a pass. Pass rates ran from 74 percent for GHK-Cu down to 34 percent for MOTS-c. The figures come from Finnrick's public lab-testing database, checked peptide by peptide on 12 November 2026.

Most peptides bought online are sold with a research-use-only label. That label means no drug manufacturing rules apply and nobody is required to check a vial before it ships. These numbers show what turns up when someone does. We do not name or rank sellers here. The question is how the market behaves, not which shop to use.

The short version

  • About 42 in 100 recent samples failed. 1,018 of 2,415, across 14 peptides.
  • No peptide came close to clean. Even the best, GHK-Cu, failed 26 percent of the time.
  • An approved name on the label does not help. Research vials of approved molecules passed at a similar rate to unapproved ones.
  • A pass is narrow. It covers identity, purity and fill for one vial, not endotoxin, sterility or the next batch.

Peptide test results, compound by compound

PeptidePass ratePassed / failed (recent)Published testsSellers testedFDA status
GHK-Cu74%143 / 511,020156Injectable not approved; FDA committee review due by Feb 2027
Ipamorelin71%139 / 5846594Not approved; FDA committee voted against
Retatrutide70%135 / 584,828417Investigational, not approved
Tirzepatide66%128 / 672,923281Approved (Mounjaro, Zepbound)
PT-14165%100 / 5315847Approved (Vyleesi)
Melanotan II62%110 / 6718446Not approved; FDA committee review due by Feb 2027
Semaglutide60%116 / 7638777Approved (Ozempic, Wegovy, Rybelsus)
BPC-15754%106 / 90950149Not approved; in HHS draft 503A policy
Cagrilintide54%107 / 9120947Investigational, not approved
Tesamorelin53%100 / 90764114Approved (Egrifta)
Sermorelin44%21 / 275115Approved product discontinued; compounded on prescription
TB-50043%84 / 11129961Not approved; in HHS draft 503A policy
CJC-129539%78 / 12034270Not approved; FDA committee voted against
MOTS-c34%30 / 599523Not approved; in HHS draft 503A policy

Ranked by pass rate among recent results with an outcome. Each name links to that peptide's page, with its numbers, what counts as a fail and its FDA status in full. Finnrick has results for 42 compounds. We include the 14 peptides with 50 or more published tests, because a pass rate built on a handful of results says little.

What the numbers show

Approval does not travel with a molecule name. Tirzepatide, semaglutide, tesamorelin and PT-141 are all approved drugs under their brand names. Research vials sold under those names passed 61 percent of the time, against 57 percent for the ten that are not approved. Approval belongs to a product made under drug manufacturing rules, and a powder with the same name on the label carries none of it.

Two compounds dominate testing. Retatrutide and tirzepatide account for 7,751 of the 12,675 published tests across these 14, about 61 percent. Retatrutide alone has 4,828, more than any other compound Finnrick lists.

Peptides sold as a pair do not test alike. Ipamorelin passed 71 percent and CJC-1295, its usual partner, 39 percent. BPC-157 passed 54 percent and TB-500 43 percent. Each vial needs its own result.

It matches the published research. A 2026 preprint by Mendias and Awan analysed 6,441 results from a public independent testing dataset and found that 41.6 to 71.1 percent failed basic quality criteria, depending on the standard applied. It has not been peer reviewed. Our page on sourcing, purity and testing covers it alongside a peer-reviewed semaglutide study.

One more figure from the same database, outside the 14 because it is not a peptide: NAD+ passed 16 of its last 68 results with an outcome, 24 percent.

How the numbers were collected

These figures use Finnrick's "Purity focus" standard, the one its public pages show. A sample passes when its purity is at least 99.5 percent and the amount in the vial is within 35 percent of the label. A sample that turns out to be a different molecule fails under every standard Finnrick uses. Endotoxin testing is not required under this standard, so a pass says nothing about endotoxin or sterility.

The pass rate counts passes and fails among the most recent results on Finnrick's public page, up to 200, and leaves out tests that came back incomplete. Finnrick says it sources samples from sellers and sends them to third-party labs, with HPLC as the main method. Its methodology page has the detail.

  • Recent results only. Older tests are not in the pass rate, so it reflects the market of the last months, not the last two years.
  • Not a random sample. These are samples Finnrick obtained and sent for testing, which may not represent every vial on sale.
  • One standard. Finnrick also publishes stricter standards with tighter purity and fill limits. Under those, more samples would fail.
  • No endotoxin in the pass rate. For an injected product that is a real gap, and the reason a full report covers more than purity.

What a test result cannot tell you

A pass rate describes a market. It does not describe the vial in your hand, a seller's next batch, or whether a compound is safe or does anything in people. Our guide on how to get peptides tested covers testing your own vial, and how to vet a peptide supplier lists the checks to run before you order. The COA check tells you whether a seller's report is genuine and matches the lab's record. Products sold as research use only are not FDA-approved drugs, and is it legal to buy peptides explains what that means for a buyer.

Buying with the lab report first

For an approved medicine, a prescription filled by a licensed pharmacy moves the testing and traceability to the pharmacy. For everything else, the report is the only evidence there is, and the numbers above are why it should come before the order, not after.

Peptide AI is building a marketplace with two ways to buy: on a prescription through licensed telehealth, for what can legally be prescribed, or from vetted suppliers with an independent lab report you read before you order. It is not open yet. Early access is here.

Questions people ask

How often do research peptides fail lab testing?

In Finnrick's public database, 1,018 of the last 2,415 results with an outcome across 14 peptides failed, about 42 percent. The rate ranged from 26 percent for GHK-Cu to 66 percent for MOTS-c.

Which peptides fail lab testing most often?

Among the 14 peptides with 50 or more published tests, MOTS-c, CJC-1295 and TB-500 had the lowest recent pass rates: 34, 39 and 43 percent.

What does a failed peptide test mean?

Under the standard used here, a sample fails if it is not the labelled molecule, if its purity is below 99.5 percent, or if the amount in the vial is more than 35 percent away from the label. The public results do not say which check each sample failed.

Does a passing test mean a peptide is safe?

No. A pass covers identity, purity and fill for the vial that was tested. It does not cover endotoxin, sterility, other vials, or whether the compound is safe or does anything in people.

Sources

  1. Methodology, Finnrick, accessed 12 November 2026
  2. Product pages and public test histories for the 14 peptides listed, and NAD+, Finnrick, accessed 12 November 2026
  3. Evaluation of research grade peptides marketed directly to consumers reveals extensive variability in purity and measured abundance (preprint, not peer reviewed), Mendias and Awan, Preprints.org, 24 April 2026
Free on iOS and Android

Log it once. See it all on one timeline.

Doses, food, training, labs, sleep and scans on one timeline. On iOS and Android.

The PeptideAI protocol screen with a weekly GLP-1 dose on it.